Recently, another significant update has emerged in China's brain-computer interface sector! Arfysica Innovation (Shanghai Shuli Intelligent Technology Co., Ltd.), a leading company in the industry, announced the completion of its RMB hundreds of millions Series B+ financing round. 36Kr reported that the amount raised in this round was RMB 160 million. This round was jointly invested by prominent institutions such as the National SME Development Fund and Oriental Fortune. The funds will be used to further advance the iteration of brain-computer interface technology and systematically build around multi-scenario applications and the industrial ecosystem.
Behind the innovative development of Arfysica Innovation is the forward-looking leadership of its founder, Dr. Wang Wei.
Source: Arfysica Innovation
Public information shows that Dr. Wang Wei, a "post-70s" individual, graduated from the University of Southampton in the UK with a Ph.D. in Biomedical Engineering and holds dual bachelor's degrees in Biomedical Engineering and Economic Law. After graduation, she directly joined Siemens Healthineers, a global medical technology giant, serving as a "Siemens Global Core Expert" and a member of the IEC International Medical Equipment Standards Committee. During her tenure, she was responsible for large-scale...Medical DeviceAnd system platform research and development and clinical application, accumulating rich international project experience and technical resources.
In 2016, Dr. Wang Wei resigned and returned to China, establishing Arfysica Innovation and its series of subsidiaries, including Germany-based Arfysica Innovation (Frankfurt). Today, she is not only a technical expert with over a hundred patents but also holds multiple roles such as an expert committee member of the China Brain-Computer Interface Industry Alliance and a member of the Shanghai Fengxian District Political Consultative Conference. It is reported that Arfysica Innovation's products primarily focus on market pain points like limb motor dysfunction, consciousness and cognitive disorders, and neurodevelopmental disorders caused by central nervous system injuries. The company emphasizes a non-invasive approach and builds integrated hardware-software engineering capabilities. It has achieved key breakthroughs across the entire technology chain, including brain signal sensing, dedicated chips, decoding algorithms, and system integration, constructing a complete closed loop from fundamental R&D and clinical validation to industrial implementation.
At the same time, the product line has entered the core departments of several top-tier tertiary hospitals in China, establishing the first-ever specialized brain-computer interface outpatient clinic and ward in the country; building the first pediatric brain-computer interface diagnosis and treatment center in China; pioneering the "physician + engineer" collaborative diagnosis and treatment model; and creating the first non-invasive brain-computer interface clinical research base.
